Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pictilisib + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**pictilisib + carboplatin + paclitaxel** is an experimental combination regimen consisting of pictilisib, an oral pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, and two established chemotherapy agents, carboplatin and paclitaxel. Pictilisib inhibits the PI3K pathway, a key signaling axis frequently dysregulated in cancer, leading to reduced cellular proliferation, survival, and tumor growth. Carboplatin is a platinum-based alkylating agent that causes DNA crosslinking and apoptosis, while paclitaxel is a taxane that stabilizes microtubules, thereby disrupting mitotic division. This three-drug combination has been studied primarily in advanced non-small cell lung cancer (NSCLC) and other solid tumors to assess safety and preliminary antitumor activity, generally as a first-line or advanced therapy. Early-phase studies have shown the combination is tolerable and has shown encouraging anti-tumor activity, with partial responses and stable disease observed[1][3][7].
- Other names
- pictilisib + carboplatin + paclitaxel
02
Targets
PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CA (Phosphoinositide 3-kinase alpha)DNAPIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pictilisib + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pictilisib + carboplatin + paclitaxel.